Glycochenodeoxycholic acid sodium salt
Based on 9 publication(s) in Google Scholar
Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC).
For research use only. We do not sell to patients.
- Purity: 98.51%
- CAS No.: 16564-43-5
- Formula: C26H42NNaO5
- Molecular Weight:471.61
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Glycochenodeoxycholic acid sodium salt
More- Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]
- ACS Appl Mater Interfaces. 2026 Jun 3;18(21):29739-29755. [Abstract]
- Hepatol Int. 2024 Jun;18(3):1040-1052. [Abstract]
- J Agric Food Chem. 2026 Jun 26. [Abstract]
- Food Funct. 2026 Jun 22. [Abstract]
- Biomolecules. 2025 Jun 28;15(7):943. [Abstract]
- Discov Oncol. 2023 Jan 11;14(1):4. [Abstract]
- bioRxiv. 2026 May 5:2026.04.30.721772. [Abstract]
- SSRN. 2022 Jan 26.
-
RT-PCR
-
RT-PCR
All Endogenous Metabolite Isoforms
MoreAll Caspase Isoforms
More
Biological Activity
|
Microbial Metabolite |
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
3.88 μM
Compound: 4b, glyco
|
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
|
[PMID: 18307294] |
| HET-1A | CC50 |
729 μM
Compound: 3, TCDCA
|
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 20713311] |
Glycochenodeoxycholic acid sodium salt (0-100 μM, 6 h) significantly increases the amount of dead cells and decreases in LC3, ATG5 and BECN1 expression in human normal liver cells, leading to Autophagosome formation inhibition[1].
Glycochenodeoxycholic acid sodium salt (5–500 μM, 24 h) exerts no induction or reduction of TGF-β mRNA expression in KMBC cells and LX-2 cells[2].
Glycochenodeoxycholic acid sodium salt (200 μM, 24 h and 48 h) enhances stemness and chemoresistance of hepatocellular carcinoma cells (HCC) by activating the STAT3 signaling pathway, suppressing the expression of apoptotic genes (Bcl10, Caspase 3, Caspase 4, Tp53, BAD) and increasing the expression of anti-apoptotic genes (Bcl2, Bcl-xl and IL10)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7 and LM3 cell lines
-
Concentration:200 μM
-
Incubation Time:24 h and 48 h
-
Result:Increased the cell viability and promoted chemoresistance treated with 5-FU (HY-90006) (120 µg/mL) and cisplatinin (10 µg/mL) in Huh7 and LM3 cell lines
-
Cell Line:L02 cells
-
Concentration:100 μM
-
Incubation Time:6 h
-
Result:Significantly reduced GFP-LC3 puncta and decreased microtubule-associated protein 1 light chain 3 (LC3), autophagy related 5 (ATG5) and beclin 1 (BECN1) expression in L02 cells.
-
Cell Line:Human normal liver cells
-
Concentration:0-100 μM
-
Incubation Time:6 h
-
Result:Decreased the TFE3 levels in a dose-dependent manner in human normal liver cells.
-
Cell Line:KMBC cells
-
Concentration:5–500 μM
-
Incubation Time:24 h
-
Result:Unaltered TGF-β mRNA expression in KMBC cells and LX-2 cells.
-
Cell Line:Huh7 and LM3 cell lines
-
Concentration:200 μM
-
Incubation Time:24 h and 48 h
-
Result:Suppressed the expression of apoptotic genes (Bcl10, Caspase 3, Caspase 4, Tp53, BAD) and increased the expression of anti-apoptotic genes (Bcl2, Bcl-xl and IL10) in Huh7 and LM3 cell lines.
Chemical Information
-
CAS No. 16564-43-5
-
Appearance Solid
-
Molecular Weight 471.61
-
Formula C26H42NNaO5
-
Color White to off-white
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NCC(O[Na])=O)=O)([H])[C@@]3([H])[C@]([C@@]4([C@](C[C@H](O)CC4)([H])C[C@H]3O)C)([H])CC1
-
Synonyms
Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]2025 Mar;12(12):e2411719. PMID: 39899681
Glycochenodeoxycholic acid sodium salt purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]
The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
-
ACS Appl Mater Interfaces
Glutathione-Chitosan Modified Methyl Eugenol Liposomes Promote Spinal Cord Injury Repair by Alleviating Neuroinflammation. [Abstract]2026 Jun 3;18(21):29739-29755. PMID: 42176032 -
Hepatol Int
Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation. [Abstract]2024 Jun;18(3):1040-1052. PMID: 38172440 -
J Agric Food Chem
Protein-Free Diet Aggravates Food Allergy Response via the Consumption of Glycochenodeoxycholic Acid in a Murine Model. [Abstract]2026 Jun 26. PMID: 42360286 -
Food Funct
Association between daidzein metabolism to equol and fecal bile acid profiles in young women. [Abstract]2026 Jun 22. PMID: 42329218 -
Biomolecules
Significant Reduction of Chenodeoxycholic Acid and Glycochenodeoxycholic Acid in the Elderly with Severe COVID-19. [Abstract]2025 Jun 28;15(7):943. PMID: 40723815
Glycochenodeoxycholic acid sodium salt purchased from MedChemExpress. Usage Cited in: Biomolecules. 2025 Jun 28;15(7):943. [Abstract]
SARS-CoV-2-stimulated THP-1 cells were treated with 10 μM or 20 μM Glycochenodeoxycholic acid (GCDCA) for 24 h. The intracellular mRNA expression levels of IL-1β, IL-8, and CXCL5 were measured by RT–qPCR.
-
Discov Oncol
Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway. [Abstract]2023 Jan 11;14(1):4. PMID: 36631680 -
bioRxiv
2026 May 5:2026.04.30.721772. PMID: 42146479 -
Solvent & Solubility
DMSO : 250 mg/mL (530.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 100 mg/mL (212.04 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (106.02 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lan W, et al. Glycochenodeoxycholic acid sodium salt impairs transcription factor E3 -dependent autophagy-lysosome machinery by disrupting reactive oxygen species homeostasis in L02 cells[J]. Toxicol Lett. 2020 Oct 1;331:11-21. [Content Brief]
[2]. Wang A, et al. Glycochenodeoxycholic acid sodium salt Does Not Increase Transforming Growth Factor-Beta Expression in Bile Duct Epithelial Cells or Collagen Synthesis in Myofibroblasts[J]. J Clin Exp Hepatol. 2017 Dec;7(4):316-320. [Content Brief]
[3]. Gonzalez B, et al. Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity. Mol Cell Biochem. 2000 Apr;207(1-2):19-27. [Content Brief]
[4]. Shi C, et al. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells[J]. Aging (Albany NY). 2020 Aug 3;12(15):15546-15555. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1204 mL | 10.6020 mL | 21.2040 mL | 53.0099 mL |
| 5 mM | 0.4241 mL | 2.1204 mL | 4.2408 mL | 10.6020 mL | |
| 10 mM | 0.2120 mL | 1.0602 mL | 2.1204 mL | 5.3010 mL | |
| 15 mM | 0.1414 mL | 0.7068 mL | 1.4136 mL | 3.5340 mL | |
| 20 mM | 0.1060 mL | 0.5301 mL | 1.0602 mL | 2.6505 mL | |
| 25 mM | 0.0848 mL | 0.4241 mL | 0.8482 mL | 2.1204 mL | |
| 30 mM | 0.0707 mL | 0.3534 mL | 0.7068 mL | 1.7670 mL | |
| 40 mM | 0.0530 mL | 0.2650 mL | 0.5301 mL | 1.3252 mL | |
| 50 mM | 0.0424 mL | 0.2120 mL | 0.4241 mL | 1.0602 mL | |
| 60 mM | 0.0353 mL | 0.1767 mL | 0.3534 mL | 0.8835 mL | |
| 80 mM | 0.0265 mL | 0.1325 mL | 0.2650 mL | 0.6626 mL | |
| 100 mM | 0.0212 mL | 0.1060 mL | 0.2120 mL | 0.5301 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
- Glycochenodeoxycholic acid
- 16564-43-5
- Chenodeoxycholylglycine
- Sodium glycochenodeoxycholate
- Endogenous Metabolite
- Apoptosis
- STAT
- BCL6
- Interleukin Related
- Caspase
- bile salt
- hepatocellular carcinoma cells
- autophagosome inhibition
- STAT3 signaling pathway
- cholestasis desease
- primary sclerosing cholangitis
- Inhibitor
- inhibitor
- inhibit